Seeking treatment for your child with growth hormone deficiency (GHD)? Once-weekly Sogroya® growth hormone treatment may be the right choice.
Sogroya® promotes growth with 1 injection per week.
In a 1-year (52-week) study of 200 children who had never been treated for growth hormone deficiency (GHD), Sogroya® was compared with a daily GH treatment (somatropin).a
Children taking Sogroya® grew 4.4 inches (11.2 cm), on average, at 1 year.
Children taking daily GH grew 4.6 inches (11.7 cm), on average, at 1 year.
aThe main goal of this study was to see if children who took Sogroya® once per week grew at the same rate as children who took the daily GH treatment.
Seeking treatment for your child with growth hormone deficiency (GHD)? Learn more about GHD.
Once-weekly Sogroya®
(n=132), %
Once-daily GH
(n=68), %
Headache
12.1%
8.8%
Common cold
11.4%
10.3%
Pain in extremity
9.1%
2.9%
The most common side effects of Sogroya® in children include:
6.1% of children taking Sogroya® experienced injection-site reactions, which included:
1.5% injection-site pain
1.5% injection-site bruising
1.5% injection-site hematoma
0.8% injection-site reaction
0.8% injection-site swelling
Talk to your child's doctor for medical advice about these and other possible side effects.
How to use Sogroya® for children
Use our helpful tools for learning how to take Sogroya®.
Actor portrayal
Get started with Sogroya®
Find out about support programs as you start your GH journey.